Chapter 47: Drug Therapy for Myasthenia Gravis, Alzheimer Disease, and Other Conditions Treated With Cholinergic Agents

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/17

flashcard set

Earn XP

Description and Tags

Vocabulary flashcards covering key concepts, medical terms, and pharmacological agents used in the treatment of myasthenia gravis, Alzheimer disease, and cholinergic disorders.

18 Terms

1
New cards

Acetylcholine

An essential neurotransmitter with high concentrations in the motor cortex and basal ganglia that plays an important role in cognitive functions, gut secretory/motor activity, and urinary bladder contraction or relaxation.

2
New cards

Myasthenia Gravis

A chronic autoimmune neuromuscular disease caused by a defect in the transmission of nerve impulses to muscles, characterized by muscle weakness that increases with activity and improves after rest.

3
New cards

Myasthenic Crisis

A severe complication of myasthenia gravis characterized by respiratory insufficiency, worsening tongue and swallowing muscle weakness, and rarely, respiratory failure.

4
New cards

Ptosis

Drooping of one or both eyelids, presenting as an early symptom of myasthenia gravis.

5
New cards

Diplopia

Blurred or double vision occurring as a symptom of myasthenia gravis.

6
New cards

Dysarthria

Impaired speech, listed as a common clinical symptom of myasthenia gravis.

7
New cards

Pyridostigmine (Mestinon)

An acetylcholinesterase inhibitor that increases acetylcholine at the neuromuscular junction to improve muscle strength; indicated for myasthenia gravis and the reversal of nondepolarizing neuromuscular blockers.

8
New cards

Cholinergic Crisis

An adverse overdose state of acetylcholinesterase inhibitors manifesting as severe weakness, respiratory depression, bradycardia, and bronchospasm.

9
New cards

Alzheimer Disease

The most common form of dementia, pathologically characterized by significant neuron loss, cortical neuron shrinkage, neuritic plaques, and neurofibrillary tangles.

10
New cards

Donepezil (Aricept)

A reversible, indirect-acting cholinergic agent that inhibits acetylcholinesterase to increase acetylcholine in the brain; indicated for mild, moderate, and severe Alzheimer disease dementia.

11
New cards

Memantine (Namenda)

An NMDA receptor antagonist that limits excess glutamate activity damaging neurons, indicated for moderate to severe Alzheimer disease.

12
New cards

Namzaric

A combination medication consisting of memantine and donepezil used in the treatment of moderate to severe Alzheimer disease.

13
New cards

Antiamyloid Antibodies

Monoclonal antibodies, such as lecanemab and donanemab, that bind beta-amyloid and promote clearance of amyloid plaques in patients with confirmed beta-amyloid plaques and mild cognitive impairment or mild dementia.

14
New cards

Amyloid-Related Imaging Abnormalities (ARIA)

An adverse effect associated with antiamyloid antibody therapy manifesting as brain edema or microhemorrhage, requiring monitoring through scheduled MRIs.

15
New cards

Bethanechol (Urecholine)

A direct-acting cholinergic agonist that stimulates muscarinic receptors to cause bladder detrusor contraction without readily crossing the blood–brain barrier, used to treat urinary retention.

16
New cards

Irreversible Anticholinesterase Agents

Highly lipid-soluble toxic compounds, including nerve gases (sarin, tabun, soman) and organophosphates (malathion, parathion), that cross the blood–brain barrier and cause widespread peripheral and central cholinergic overstimulation.

17
New cards

Pralidoxime

A pharmacologic agent administered during irreversible anticholinesterase toxicity to relieve neuromuscular blockade.

18
New cards

Atropine

An antidote kept available to counteract excessive muscarinic effects during cholinergic crises or irreversible anticholinesterase toxicity.